TY - JOUR AU - 전대원 DA - 2014/11 PY - 2014 UR - http://ovidsp.tx.ovid.com/sp-3.28.0a/ovidweb.cgi?QS2=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 UR - http://hdl.handle.net/20.500.11754/51231 AB - AIM:: Although numerous animal studies suggest that probiotic therapy has beneficial effects in various liver diseases, the evidence for beneficial effects in human liver disease is controversial. This study was carried out to investigate the efficacy of probiotic therapy in alleviating small intestinal bacterial overgrowth (SIBO) and permeability in chronic liver disease. METHODS:: Fifty-three patients with chronic liver disease were randomized to either probiotic therapy or placebo. Six bacterial species were used: Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus. After 4 weeks, changes in the composition of fecal bacteria, SIBO, intestinal permeability, and clinical symptoms were examined. RESULTS:: Three of the six probiotic species, B. lactis, L. rhamnosus, and L. acidophilus, increased in the feces of the probiotic therapy group (P PB - LIPPINCOTT WILLIAMS AND WILKINS KW - Feces KW - microbiology KW - Female KW - Hepatitis B KW - Chronic KW - diagnosis KW - therapy KW - Hepatitis C KW - Chronic KW - Humans KW - Intestine KW - Small KW - metabolism KW - Liver Diseases KW - Alcoholic KW - Male KW - Middle Aged KW - Permeability KW - Probiotics KW - Republic of Korea KW - Time Factors KW - Treatment Outcome TI - Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease IS - 12 VL - 26 DO - 10.1097/MEG.0000000000000214 T2 - EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY ER -